(Q53293730)

English

Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma.

scientific article published on 25 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. (English)

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Kato

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

T Mori

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

K Yokoyama

3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

Y Tsukada

4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

T Ueda

5

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

T Shimizu

6

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

S Okamoto

7

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

language of work or name

0 references

publication date

25 October 2010

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

Bone Marrow Transplantation

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

46

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

7

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

923-928

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

https://scigraph.springernature.com/pub.10.1038/bmt.2010.243

0 references

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

21 January 2018

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.243

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2010.243

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20972471

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53293730&oldid=1582965163"